Servier, an independent international pharmaceutical group, has published its financial results for the 2023-2024 financial year and highlighted the milestones that marked the year, particularly in R&D.

Key Highlights

• The 2023/2024 financial year marks a key milestone, achieved a year ahead of schedule, highlighting the success of our 2030 strategy.
• Consolidated revenue for 2023/2024 reached €5.902 billion, a 10.8% increase compared to the previous year, fueled by a strong rise in international sales across all business segments.
• Significant scientific breakthroughs were made in CMVD and oncology, further strengthening our leadership in these fields.
• Neurology, a key growth driver for the Group’s future, mirrors our strategic focus on oncology, demonstrating our commitment to advancing both areas.
• Our R&D pipeline has made remarkable strides, primarily emphasizing oncology and neurology, paving the way for continued innovation.